Margaret G. Mcglynn - 01 Jun 2021 Form 4 Insider Report for VERTEX PHARMACEUTICALS INC / MA (VRTX)

Role: Director
Signature: /s/ Sabrina Yohai, Attorney-in-Fact
Issuer symbol: VRTX
Transactions as of: 01 Jun 2021
Net transactions value: $0
Form type: 4
Filing time: 03 Jun 2021, 16:09:30 UTC
Next filing: 14 Jun 2021
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	VRTX	Common Stock	Disposed to Issuer		-699	-39%		1,099	01 Jun 2021	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	VRTX	Deferred Stock Units	Award		+699	+18%		4,688	01 Jun 2021	Common Stock	699		Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Upon the vesting of restricted stock units granted to Ms. McGlynn on June 1, 2020, Ms. McGlynn deferred the receipt of 699 shares of common stock and received instead 699 deferred stock units pursuant to the Company's deferred compensation plan. As a result, Ms. McGlynn is reporting the disposition of 699 shares of common stock in exchange for an equal number of deferred stock units.
F2	Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McGlynn's service on our board of directors, (ii) a change of control of our company and (iii) Ms. McGlynn's disability or death.